In the APOLLO registrational trial, patients with EGFR T790M-positive advanced NSCLC after disease progression on a first- or second-generation EGFR-TKI achieved a median PFS of 12.4 months, and the toxicity profile was tolerable (Lu et al., 2022a). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.